Therapeutic Antibodies – Multimedia

Glycosylation refers to the formation of linkages with glycosyl groups, covalently attaching a carbohydrate to another molecule. Antibody glycosylation is critical due to the role carbohydrates play in modulating effector functions which affect safety and efficacy of therapeutic antibodies.

Download this free listicle to learn more about the current scope and future prospects for therapeutic antibody engineering.

Therapeutic monoclonal antibodies (mAbs) are highly heterogeneous molecules due to being composed of a large number of variants. When the variants are present in the pharmaceutical protein, it is possible their biological activity could be altered.

Antibody–drug conjugates (ADCs) are monoclonal antibodies to which a cytotoxic small molecule drug is chemically linked. The structures of ADCs are more complex than their corresponding antibodies.

Antibodies are subject to instability issues due to chemical and physical instabilities and these effects can change the pharmacokinetics of the antibody. For this reason, produced antibodies must be thoroughly tested before they can be applied for treatment of patients.

In biotherapeutic process development, evaluating and tracking potential product quality attributes (PQAs) is crucial to ensure quality, safety, and efficacy.

Antibody-based derivatives have received increased attention as therapeutics in biopharmaceutical development because of their unique capacity to engage multiple molecular targets, engage immune effector cells or even penetrate tissues previously inaccessible to conventional mAbs.

Download this list to explore current immunotherapeutic strategies, recent regulatory approvals and the future of cancer therapy.

Over recent years, single-cell sequencing has become a method ubiquitously used across several different areas of biological research. Why have so many researchers so rapidly adopted this relatively novel set of techniques and how can they be applied?

The changing landscape for antibody-derived therapeutics, such as bi-specific monoclonal antibodies, Fab fragments and Fc-fusion proteins brings new purification challenges in the downstream processing of these molecules. Standard chromatography resins, such as Protein A, may not result in the most efficient purification process.